SI-B001

DRUG11 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Colorectal CancerEsophageal Squamous Cell CarcinomasHead and Neck Squamous Cell CarcinomaLocally Advanced or Metastatic Epithelial TumorNon Small Cell Lung CancerNon-small Cell Lung AdenocarcinomaNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck

Phase 1

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Active, not recruitingNCT04603287

Sichuan Baili Pharmaceutical Co., Ltd.Locally Advanced or Metastatic Epithelial Tumor

Start: 2020-04-17End: 2025-12-31Updated: 2025-09-26

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

RecruitingNCT05668858

Sichuan Baili Pharmaceutical Co., Ltd.Squamous Cell Carcinoma of Head and Neck

Start: 2023-02-10End: 2027-12-31Target: 130Updated: 2025-09-26

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

RecruitingNCT05949606

Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2023-10-30End: 2027-12-31Target: 160Updated: 2025-09-26

Phase 2

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Active, not recruitingNCT05020457

Sichuan Baili Pharmaceutical Co., Ltd.Non Small Cell Lung Cancer

Start: 2021-12-07End: 2025-12-31Updated: 2025-09-26

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Active, not recruitingNCT05020769

Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2022-01-06End: 2025-12-31Updated: 2025-09-26

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Active, not recruitingNCT05022654

Sichuan Baili Pharmaceutical Co., Ltd.Esophageal Squamous Cell Carcinomas

Start: 2021-12-13End: 2025-12-31Updated: 2025-09-26

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

TerminatedNCT05039944

Sichuan Baili Pharmaceutical Co., Ltd.Colorectal Cancer

Start: 2021-11-30End: 2022-06-06Updated: 2024-07-18

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Active, not recruitingNCT05044897

Sichuan Baili Pharmaceutical Co., Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2021-10-20End: 2025-12-31Updated: 2025-09-26

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Active, not recruitingNCT05054439

Sichuan Baili Pharmaceutical Co., Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2021-12-22End: 2025-12-31Updated: 2025-09-26

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RecruitingNCT06668961

Sichuan Baili Pharmaceutical Co., Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2024-11-07End: 2026-11-01Target: 60Updated: 2026-01-21

Phase 3

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Active, not recruitingNCT05943795

Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung

Start: 2023-07-14End: 2026-07-31Updated: 2025-06-29

Related Papers

SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.

Journal of Clinical Oncology2023-06-0117 citations

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2023-06-0110 citations